Compare Amgen, Inc. (AMGN) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs IQIYI Inc - ADR — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while IQIYI Inc - ADR trades at $1.11 (market cap $1.09B). The key difference: Amgen, Inc. is far larger — about 179.9× IQIYI Inc - ADR's market cap, and Amgen, Inc. pays a 2.77% dividend while IQIYI Inc - ADR pays none. Which is the better fit depends on your goals.
| AMGN | IQ | |
|---|---|---|
Market Cap | $196.12B | $1.09B |
Sector | Health | Media |
52-Week High | $388.16 | $2.79 |
52-Week Low | $271.18 | $0.96 |
Enterprise Value | $241.41B | $2.65B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
IQ trades at $1.13, down 0.88% on the day, with technical indicators neutral and mixed earnings history. Revenue declined to $27.29B in 2025 with a net loss of $206.31M, though valuation ratios like P/S of 0.28 and P/B of 0.57 suggest potential undervaluation. Recent news highlights AI initiatives and leadership changes, while cash flow trends show volatility with a net inflow of $787.41M in 2025.
The outlook is cautious; analyst consensus is split with 50% buy ratings but profitability concerns persist. Risks include revenue declines, competitive pressures in streaming, and debt levels. Upside potential exists if AI-driven content strategies revive growth, but near-term volatility is likely amid earnings uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
